1. Robert McCarthy, PhD
5 Riverside Drive, Apt 17C
New York, NY 10023
646-269-1554
Email: robertfgmccarthy@gmail.com
PROFESSIONAL EXPERIENCE:
2015-- Scientific Director, Medscape Education
• Responsible for the development of CME programs for the Medscape Ex-
USA website, with particular emphasis on cardiometabolic disorders,
rheumatology, and neurology
2015--2015 Medical Comms Program Direction/Medical Writing Services
• Clients include Med-Val, Unified/Wild Type, AdelphiGroup US
2012—2014 Vice President, Medical Director, Edelman Bioscience
Scientific lead:
• Secukinumab, a cytokine inhibitor in development by Novartis for a range of
autoimmune disorders (eg, psoriasis, psoriatic arthritis, arthritides, uveitis,
Crohn’s disease, MS).
• Responsible for development/delivery of all scientific content, including
o strategy, tactics, and execution of med comms plans and publications
plans (Phase 3 data Ms recently accepted by NEJM)

2. o extensive work on primary publications (Phase 3 trials), reviews,
abstracts/posters
o extensive work on symposia content; MSL training content; advisory board
content; Congress booth panel content
Please see pages 3-7 of the resume for a more detailed account of therapeutic
category/agent experience
2008-2012 Director, Scientific Services, Adelphi US
Scientific lead:
• Liraglutide, a GLP-1 receptor agonist developed by Novo Nordisk and
approved as Victoza, for the treatment of Type 2 diabetes
• Riociguat, a soluble guanylate cyclase stimulator developed by Bayer, for the
treatment of pulmonary hypertension
• Kogenate, a recombinant Factor VIII replacement therapy, developed and
marketed by Bayer, for the treatment of hemophilia-Type A
• Faldaprevir, a protease inhibitor developed by Boehringer Ingelheim, for the
treatment of hepatitis C
• Oversaw project work on a range of other compounds and devices, including
vedolizumab, α4β7 integrin antagonist in development for Crohn’s disease and
ulcerative colitis; donepezil (Aricept), an acetylcholinesterase inhibitor, indicated
for Alzheimer’s disease; and the Ethicon harmonic knife, for endoscopic surgery
• Responsible for development/delivery of all scientific content, including strategy,
tactics, and execution of med comms plans and publications plans. Worked
extensively on primary publications (Phase 3 trials), reviews, abstracts/posters;
symposia content; MSL training content.
• Managed a staff of medical writers and editors (that varied in size from 3 to 5
med writers editors), as well as freelance contractors
o Apportioned workloads, reviewed work product, determined hours
required to complete projects,
o Provided leadership in mentoring staff development by helping to set
goals and assess acquisition of new skills

3. 2003-2008 Manager, Medical Writing, EURO RSCG Genecom (Havas)
• Responsible for oversight and production of medical
communications/publications for such compounds as
o Tekturna and Diovan (Novartis, hypertension);
o Avandia, Lantus (GSK, diabetes);
o Actos (Takada, diabetes);
o Lovenox (Aventis, DVT);
o Rimonabant (Sanofi, weight loss);
o Lunesta (Sunovion, insomnia);
o Xopenex (Sunovion, asthma)
• Managed Genecom’s medical writing group (in-house personnel and freelance;
varied in size from 2 to 5 med writers editors)
o Apportioned workloads, reviewed work product, determined hours
required to complete projects,
o Provided leadership in mentoring staff development by helping to set
goals and assess acquisition of new skills
In the 1990s I worked as a healthcare journalist specializing in managed care/managed
markets. I was for 3 years the managing editor of Business and Health magazine. I
wrote for a number of publications the covered the business of healthcare provision,
including Managed Care Today, Drug-Benefit Trends, and Drug Topics. For a number
of years I wrote two newsletters: 3rd
Party Pharmacy and Managed Care Digest. In the
early ‘90s I researched and wrote what was probably among the first white papers on

4. disease-state management for the healthcare division of what was then
PriceWaterhouseCoopers.
Please see attached CV for a more comprehensive discussion of agency work/life
experience
EDUCATION PhD, English, Rutgers University
MA, English, Rutgers University
BA, Philosophy, King’s College

5. Therapeutic Category Experience
Disease State Agent Company Type of work
Metabolic
Disorders
Insulin
glargine/Lantus
(T2D)
Sanofi Aventis Med Comms: Ad Boards, Symposia,
HEOR Presentation
Pioglitazone/Actos
(T2D)
Takeda Med Comms: Ad Boards, Symposia,
Webinars, MSL training content
Rosiglitazone/Avan
dia (T2D)
GSK Ad Boards, Symposia Content, MSL
training materials
Liraglutide/Victoza
(T2D)
Novo Nordisk Review papers; Pubs Plan
Development; Ad Boards
Rimonabant
(Obesity)
Sanofi Synthelabo Primary papers and posters; Symposia
content; Ad Boards
Virologic
Disorders
Brecanivir (HIV) GSK Messaging Platform; Lexicon
Development
Telaprevir/Incivek
(HepC)
Vertex Messaging Platform; Lexicon
Development
Faldaprevir (HepC) BI Review papers; Pubs plan
development; Ad Boards

6. Therapeutic Category Experience
Disease State Agent Company Type of work
Cardiovascular
Disorders
Valsartan/Diovan
(HTN)
Novartis Med Comms: Ad Boards, Symposia,
Dinner Meeting Content
Aliskirin/Tekturna
(HTN)
Novartis Med Comms: Ad Boards, Symposia,
Webinars, MSL training content
Prasugrel (platelet
activation inhibitor)
Daiichi
Sankyo/Lilly
Ad Boards
Ticagrelor (platelet
activation inhibitor)
AstraZeneca SWOT analysis, messaging based
around MOA differentiation
Amlopidine/Norvasc
(ACS)
Pfizer Unmet needs symposium development
Enoxaparin/Lovenox
(DVT, PE, ACS)
Sanofi Aventis Med Comms and Publications;
Development of marketing materials
Drug-eluting stents Boston Scientific
Urokinase/
Abbokinase
(Thrombolysis)
Abbott Slide-based MSL Learning Modules
Autoimmune
Disorders
Secukinumab
(Psoriasis;
Arthritides)
Novartis Publications; Med Comms: Ad Boards,
Symposia, MSL Training Materials

7. Therapeutic Category Experience
Disease State Agent Company Type of work
Dermatologic
Disorders
Benzaclin (Acne) Dermik Med Comms: Ad Boards, Symposia, Draft
Clinical Practice Guidelines
Finacea (Rosacea) Bayer Med Comms: Ad Boards, Symposia,
Publications (in vitro studies; reviews)
Asthma/Allergy Xolair (Allergic
Asthma)
Genentech Review paper: Unmet Tx Needs in
Asthma/Allergy
Xopenex (Asthma) Sepracor Review papers; Med Comms: Ad Boards,
Symposia, Dinner Meeting Materials
Norastemizole
(Allergy)
Sepracor Primary publications and reviews; Med
Comms: Ad Boards, Symposia
Desloratadine/
Clarinex (Allergy)
Schering-Plough Primary publications and reviews
Hematologic
Disorders
Xigris (Sepsis) Eli Lilly Review paper: Current Understanding of
Pathophysiology and New Treatments
Kogenate
(Hemophilia A)
Bayer Publications (Primary papers and
reviews; abstracts and posters); Med
Comms: Ad Boards, Symposia; MSL
training materials

8. Therapeutic Category Experience
Disease State Agent Company Type of work
Hematologic
Disorders
C1 esterase
inhibitor/Cynrize
(Hereditary
Angioedema)
Shire Review papers; MSL slides; Ad Board
Materials
CNS Disorders Methylphenidate/
Concerta (ADHD)
Janssen Review papers; Ad Board Materials
Oxycodone/OxyConti
n (Neuropathic Pain)
Purdue Pharma Ad Board Materials; Pain Management
Videos
Eszopiclone/
Lunesta (Sleep
Disorders)
Sepracor Review Papers; Ad Board Presentations;
Monographs: Competitor Analyses
Donepezil/Aricept
(Alzheimer’s)
Eisai/Pfizer Primary and Review Publications; Ad
Board Materials; MSL Training
Presentations
Dyslipidemia Niacin/Statin/
Simcor
AbbVie Unmet needs analyses in lipid reduction
Torcetrapib Pfizer Lexicon development; messaging
Oncology CME/Prostate Cancer NA Review paper: Current Treatment
Standards and New Therapeutic
Modalities

9. Therapeutic Category Experience
Disease State Agent Company Type of work
Pulmonary/Respi
ratory Disorders
Adempas/Riociguat
(Pulmonary
Hypertension)
Bayer Ad Board Materials; Symposia; Meeting
reports; Competitor Analysis
Endoscopic
Surgery
Harmonic Knife; ETS-
Flex Linear Cutter
Ethicon Review Papers; Development of an
Endoscopic Surgical Equipment Ratings
Scale
Ocular Disorders Latanoprost/
Xalatan (Glaucoma)
Pfizer Messaging Platform; Lexicon
Development
Aflibercept (AMD) Regeneron Messaging Platform: Ad Boards
Erectile
Dysfunction
Vardenafil/Levitra GSK Primary Publications; Messaging
Platforms
Women’s
Health/Menopa
use
Duavee/Conjugated
estrogens +
Bazedoxifene
Pfizer/Wyeth Messaging Platforms/Lexicon
development

10. Therapeutic Category Experience
Disease State Agent Company Type of work
Pulmonary/Respi
ratory Disorders
Adempas/Riociguat
(Pulmonary
Hypertension)
Bayer Ad Board Materials; Symposia; Meeting
reports; Competitor Analysis
Endoscopic
Surgery
Harmonic Knife; ETS-
Flex Linear Cutter
Ethicon Review Papers; Development of an
Endoscopic Surgical Equipment Ratings
Scale
Ocular Disorders Latanoprost/
Xalatan (Glaucoma)
Pfizer Messaging Platform; Lexicon
Development
Aflibercept (AMD) Regeneron Messaging Platform: Ad Boards
Erectile
Dysfunction
Vardenafil/Levitra GSK Primary Publications; Messaging
Platforms
Women’s
Health/Menopa
use
Duavee/Conjugated
estrogens +
Bazedoxifene
Pfizer/Wyeth Messaging Platforms/Lexicon
development